{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:36:46Z","timestamp":1792255006883,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000980","name":"Arthritis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.semarthrit.2026.152973","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:53:18Z","timestamp":1774486398000},"page":"152973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease"],"prefix":"10.1016","volume":"78","author":[{"given":"Gregory C","family":"McDermott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi J","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152973_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-019-0275-x","article-title":"Mechanisms of lung disease development in rheumatoid arthritis","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0002","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis - a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0003","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0004","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/kez177","article-title":"The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment","volume":"58","author":"Duarte","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00296-004-0472-y","article-title":"Pulmonary involvement in rheumatoid arthritis","volume":"25","author":"Bilgici","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0006","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis-interstitial Lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0007","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/acr.24856","article-title":"Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial Lung disease: a population-based cohort","volume":"74","author":"Samhouri","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0008","article-title":"2023 American college of rheumatology (ACR)\/American college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041082","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0010","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0011","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease","author":"Antoniou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0012","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0013","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0014","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0015","article-title":"Association of abatacept with lower mortality risk compared to Rituximab in rheumatoid arthritis-associated interstitial lung disease: an emulated target trial","author":"Shih","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0017","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/acr.24043","article-title":"Performance of administrative algorithms to identify interstitial lung disease in rheumatoid arthritis","volume":"72","author":"England","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2019.11.010","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","volume":"50","author":"Kang","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0019","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamainternmed.2024.5738","article-title":"Supplemental oxygen use, outcomes, and spending in patients with COPD in the Medicare competitive bidding program","volume":"184","author":"Duan","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0020","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0022","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cpt.329","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219907","article-title":"TNF superfamily control of tissue remodeling and fibrosis","volume":"14","author":"Steele","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0024","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0025","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0026","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor a\u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0027","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152561","article-title":"Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Zhang","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206657","article-title":"Targeted therapy in rheumatoid-arthritis-related interstitial lung disease","volume":"12","author":"Harrington","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","article-title":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","volume":"54","author":"Nakashita","year":"2016","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0031","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010277","article-title":"Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0033","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.reuma.2022.03.005","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: treatment","volume":"18","author":"Narv\u00e1ez","year":"2022","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0034","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0035","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0036","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0037","doi-asserted-by":"crossref","first-page":"317","DOI":"10.46497\/ArchRheumatol.2024.10199","article-title":"Rituximab for rheumatoid arthritis-related interstitial lung disease: a systematic review and meta-analysis","volume":"39","author":"Krishna Boppana","year":"2024","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0038","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/resp.13419_192","article-title":"Effect of tocilizumab on interstitial lung disease in patients with rheumatoid arthritis","volume":"23","author":"Otsuji","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0039","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0041","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00296-021-04835-1","article-title":"A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease","volume":"41","author":"Cronin","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0043","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0044","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1117","article-title":"Causal inference from longitudinal studies with baseline randomization","volume":"4","author":"Toh","year":"2008","journal-title":"Int J Biostat"},{"key":"10.1016\/j.semarthrit.2026.152973_bib0045","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:58:07Z","timestamp":1789667887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"alternative-id":["S0049017226000624"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152973","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152973"}}